Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Inclusion Criteria: * Received radical resection of non-small cell lung cancer without prior anti-tumor therapies including radiotherapy, chemotherapy, target therapy and immunotherapy. * Histologically diagnosed Non-small cell lung cancer based on the judgement of at least 2 pathologists. * Stage IA with high risk factors including micropapillae or solid components, vascular invasion, spread through air spaces, low differentiation, tumor budding and insufficient lymph node dissection; Stage IB with or without high-risk factors. The pathological stage is based on the 8th edition of AJCC lung cancer staging. * EGFR mutation positive according to NGS testing by tissue, including deletions in exon 19, L858R, S768I, G719X, L861Q, T790M mutations et al. * ECOG performance status 0-1. * Sufficient organ function in liver, renal, kidney and hematology. * With written signed informed consent form, ability to report adverse events, and good adherence to clinical study. Exclusion Criteria: * Lung cancer with small cell or neuroendocrine cancer cell. * EGFR exon 20 insertion positive. * Concurrent with other diver mutations including alterations in ALK, ROS1, MET et al. * Women who are pregnant or breastfeeding. * Use of CYP3A4 strong depressant within 7 days or CYP3A4 strong inducer within 21 days prior to initial administration, use of other anti-tumor treatment including traditional Chinese medicine within 14 days before enrollment. * Concurrent with other malignancies excluding c…